New York2 startups are commercializing heritable embryo gene editing.
Preventive and Origin Genomics combine gene editing with IVF to correct germline mutations — edits inherited by all future descendants of treated embryos.
Disease advocacy groups whose communities are targeted have stayed silent as both companies move toward clinical trials.
Sources: Undark